TrialClinical pharmacology in drug development2026
Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double-Blind, Single-Dose, Parallel-Group Study in Healthy Chinese Participants.
Yehua Xie et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.